If so, we need to understand how YAP becomes activated downstream of LOF AXIN1, and whether targeting YAP, such as using TNKS inhibitors, will lead to regression of HCC with LOF AXIN1 mutations. Here, AXIN1 is linked to hepatocellular carcinoma.